Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Salarius Update

14 Feb 2022 07:00

RNS Number : 5074B
Tekcapital plc
14 February 2022
 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

14 February 2022

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

 

Portfolio Company Update: Salarius, Ltd. ("Salarius")

Update on MicroSalt and SaltMe! Snacks - Bulk MicroSalt order received from FXM

 

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products from investing in university technology that can improve people's lives, is please to provide an update on MicroSalt, Inc., the U.S. operating subsidiary of Salarius, Ltd.

 

MicroSalt continues its expansion in the low salt and low sodium markets and is pleased to announce that it has executed its first bulk MicroSalt® order through FXM, our Mexican based distribution partner (see announcement dated 24 September 2020). "This order is a testament to the timeliness of our products and our ability to customize our production for the Mexican market" said Rick Guiney, MicroSalt's CEO.

 

"This follows on the heels of the placement of MicroSalt's SaltMe® brand of low sodium potato chips into over 1,350 retail stores nationwide, to-date. We are also pleased to report sales of MicroSalts's SaltMe Chips reflect significant growth to $125,000. in January 2022 vs. $3,000. for January 2021, an approximately 40-fold increase. Whilst it's too early to place a firm number of estimated revenues for our chips in 2022 we believe that we may see significant sales growth in the current year," said Guiney.

"The health issues surrounding the excess consumption of sodium cannot be overstated and the ever-increasing profile of low salt and sodium products serves not only as a launching pad for MicroSalt but acts as a foundational tool in our fight to improve the health and wellness of our family, friends, neighbors and the world." Said Guiney

MicroSalt is a subsidiary of portfolio company, Salarius. MicroSalt aims to revolutionize the food industry with its patented sodium microparticle, that delivers the full-flavour experience of salt with roughly half the sodium. MicroSalt® is all-natural, non-GMO, and Kosher.

 

About Salarius Ltd.

Salarius, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples' lives with better-for-you snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption.

 

Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

 

To learn more about MicroSalt please visit https://Salarius.co/. 

To learn more about SaltMe! snacks please visit https://saltme.com/.

 

Tekcapital owns 97.2% of the share capital of Salarius Ltd. and approximately 80% of the share capital of MicroSalt Inc., its U.S. subsidiary.

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

For further information, please contact:

Tekcapital Plc 

Via Flagstaff IR

Clifford M. Gross, Ph.D. 

SP Angel  Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison / Charlie Bouverat (Corporate Finance)

Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Salarius that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Salarius' and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Salarius or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Salarius nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDTJMRTMTMBBRT
Date   Source Headline
10th Apr 20257:00 amRNS-RInnovative Eyewear Receives EU Certification
31st Mar 20255:34 pmRNSUnaudited Results to 31 December 2024
20th Mar 20257:00 amRNS$0.35m Contract Win
13th Mar 20257:00 amRNSCorporate Update & 2025 Outlook
17th Feb 20257:00 amRNS2024 Review - Year End Portfolio Update
14th Feb 20251:22 pmRNSNotification of Major Holdings
3rd Feb 20257:00 amRNSOversubscribed Fundraising of £2.3Million
30th Jan 20257:00 amRNS-RInnovative Eyewear announces Key Partnership
22nd Jan 202511:14 amRNSNotification of Major Holdings
21st Jan 20257:00 amRNSGuident Receives Significant New Patent Coverage
17th Jan 20259:13 amRNSPlacing of £0.5 million (c.$0.6m)
15th Jan 20257:00 amRNSGuident Corp. Appointment of Investment Banker
20th Dec 20247:00 amRNSPortfolio Company Update - Guident Ltd
4th Dec 20247:00 amRNSIssue of Shares to Advisers
25th Nov 20249:13 amRNS-RPortfolio Company Update - Innovative Eyewear
20th Nov 20244:26 pmRNSNotification of Major Holdings
20th Nov 20247:00 amRNSCorporate Update
15th Nov 20247:00 amRNSFundraising of £1.0 Million
30th Oct 20247:00 amRNSNew and Follow-on B2B Customer Orders
8th Oct 20247:00 amRNSCorporate Update
2nd Oct 20248:00 amRNSTekcapital Spins out GenIP onto AIM
25th Sep 20247:00 amRNSHalf Year Results
18th Sep 20247:58 amRNSGenIP plc Schedule One
16th Sep 20247:00 amRNSMultiple Placements of Products and B2B Progress
13th Sep 20241:37 pmRNSHolding(s) in Company
29th Aug 20247:00 amRNSPortfolio Company Update Innovative Eyewear Inc
13th Aug 20247:00 amRNSInnovative Eyewear 2nd Q24 Revenue increased 82%
1st Jul 202411:21 amRNSGrant of Share Options
21st Jun 20244:20 pmRNSResults of Annual General Meeting
30th May 20247:00 amRNSPortfolio Company Update - Innovative Eyewear
22nd May 20247:00 amRNSFinal Results year ended 31 December 2023
2nd May 20247:00 amRNSPortfolio Company Update Guident Q1 2024
26th Apr 20247:00 amRNSInnovative Eyewear Canadian Partnership
25th Apr 20247:00 amRNSInnovative Eyewear Patent Filings
18th Apr 20247:00 amRNSInnovative Eyewear Signs Brand Ambassador
17th Apr 20247:00 amRNSInnovative Eyewear Distribution Partnership
9th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
5th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
28th Mar 202410:20 amRNSNotification of Major Holdings
7th Mar 202411:15 amRNSNotification of Major Holdings
6th Mar 20247:00 amRNSIntellectual Property Update
29th Feb 20247:51 amRNSFundraising of £2.0 million
19th Feb 20247:00 amRNSPortfolio Company Update : Guident Ltd
15th Feb 202410:31 amRNSNotification of Major Holdings
15th Feb 20247:00 amRNSGuident Expands its Strategic Partnership
13th Feb 20242:24 pmRNSNotification of Major Holdings
1st Feb 20247:15 amRNSMicroSalt Admission to AIM First Day of Dealings
1st Feb 20247:01 amRNSNotice of Presentation on Investor Meet Company
24th Jan 20247:00 amRNSBellescura Plc - Disposal of Shares
12th Jan 20244:31 pmRNSLoan Agreement with Innovative Eyewear Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.